Judy C. Boughey, MD
“Inflammatory breast cancer represents the aggressive end of the spectrum of breast cancer at presentation. It is encouraging It to see the high 5-year breast cancer–specific survival rates reported in this cohort of 114 women,” said Judy C. Boughey, MD, a breast surgeon at the Mayo Clinic, Rochester, and Chair of the Publications Committee of the American Society of Breast Surgeons.
“This study supports that the current management of these patients with neoadjuvant chemotherapy, modified radical mastectomy, and postmastectomy radiation is the optimal multimodal approach. The improvements in systemic therapy, with increased use of directed therapy, together with appropriate local-regional therapies, are likely responsible for the improvement in survival over historical cohorts,” Dr. Boughey said. ■
Disclosure: Dr. Boughey reported no conflicts of interest.
Contemporary triple-modality therapy achieves excellent locoregional tumor control of inflammatory breast cancer, with only 4 locoregional recurrences out of 114 patients treated at The University of Texas MD Anderson Cancer Center, Houston. The investigators described their approach at the...